<SEC-DOCUMENT>0000929638-24-002961.txt : 20240823
<SEC-HEADER>0000929638-24-002961.hdr.sgml : 20240823
<ACCEPTANCE-DATETIME>20240823160226
ACCESSION NUMBER:		0000929638-24-002961
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240403
FILED AS OF DATE:		20240823
DATE AS OF CHANGE:		20240823

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Nippon Shinyaku Co Ltd
		CENTRAL INDEX KEY:			0001361865
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			M0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34058
		FILM NUMBER:		241236239

	BUSINESS ADDRESS:	
		STREET 1:		14 NISHINOSHO MONGUCHI CHO
		STREET 2:		KISSHOIN MINAMIKU
		CITY:			KYOTO
		STATE:			M0
		ZIP:			00000
		BUSINESS PHONE:		81 75 321 9104

	MAIL ADDRESS:	
		STREET 1:		14 NISHINOSHO MONGUCHI CHO
		STREET 2:		KISSHOIN MINAMIKU
		CITY:			KYOTO
		STATE:			M0
		ZIP:			00000

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAPRICOR THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211
		BUSINESS PHONE:		(310) 358-3200

	MAIL ADDRESS:	
		STREET 1:		8840 WILSHIRE BLVD
		STREET 2:		2ND FLOOR
		CITY:			BEVERLY HILLS
		STATE:			CA
		ZIP:			90211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nile Therapeutics, Inc.
		DATE OF NAME CHANGE:	20070920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2024-04-03</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001133869</issuerCik>
        <issuerName>CAPRICOR THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>CAPR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001361865</rptOwnerCik>
            <rptOwnerName>Nippon Shinyaku Co Ltd</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>14 NISHINOSHO MONGUCHI CHO</rptOwnerStreet1>
            <rptOwnerStreet2>KISSHOIN MINAMIKU</rptOwnerStreet2>
            <rptOwnerCity>KYOTO</rptOwnerCity>
            <rptOwnerState>M0</rptOwnerState>
            <rptOwnerZipCode>00000</rptOwnerZipCode>
            <rptOwnerStateDescription>JAPAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock, par value $0.001 per share</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2145922</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Warrant (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.7</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2024-04-03</value>
            </exerciseDate>
            <expirationDate>
                <value>2030-10-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>2145922</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On September 29, 2023, the reporting person entered into a securities purchase agreement with Capricor Therapeutics, Inc., a Delaware corporation (the &quot;Issuer&quot;), pursuant to which the reporting person purchased (a) 2,145,922 shares of common stock, $0.001 par value per share (the &quot;Common Stock&quot;), of the Issuer's Common Stock and (b) warrants to purchase 2,145,922 shares of the Issuer's Common Stock (the &quot;Warrants&quot;). The combined offering price per share of Common Stock and the accompanying Warrant was $4.66. The Warrants will expire seven years from October 3, 2023 (the date of issuance).</footnote>
        <footnote id="F2">The Warrants are fully exercisable.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Takanori Edamitsu, Director, Business Management &amp; Sustainability</signatureName>
        <signatureDate>2024-08-23</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
